Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study

PLoS Med. 2021 May 26;18(5):e1003567. doi: 10.1371/journal.pmed.1003567. eCollection 2021 May.

Abstract

Background: Plasmodium vivax has been proposed to infect and replicate in the human spleen and bone marrow. Compared to Plasmodium falciparum, which is known to undergo microvascular tissue sequestration, little is known about the behavior of P. vivax outside of the circulating compartment. This may be due in part to difficulties in studying parasite location and activity in life.

Methods and findings: To identify organ-specific changes during the early stages of P. vivax infection, we performed 18-F fluorodeoxyglucose (FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) at baseline and just prior to onset of clinical illness in P. vivax experimentally induced blood-stage malaria (IBSM) and compared findings to P. falciparum IBSM. Seven healthy, malaria-naive participants were enrolled from 3 IBSM trials: NCT02867059, ACTRN12616000174482, and ACTRN12619001085167. Imaging took place between 2016 and 2019 at the Herston Imaging Research Facility, Australia. Postinoculation imaging was performed after a median of 9 days in both species (n = 3 P. vivax; n = 4 P. falciparum). All participants were aged between 19 and 23 years, and 6/7 were male. Splenic volume (P. vivax: +28.8% [confidence interval (CI) +10.3% to +57.3%], P. falciparum: +22.9 [CI -15.3% to +61.1%]) and radiotracer uptake (P. vivax: +15.5% [CI -0.7% to +31.7%], P. falciparum: +5.5% [CI +1.4% to +9.6%]) increased following infection with each species, but more so in P. vivax infection (volume: p = 0.72, radiotracer uptake: p = 0.036). There was no change in FDG uptake in the bone marrow (P. vivax: +4.6% [CI -15.9% to +25.0%], P. falciparum: +3.2% [CI -3.2% to +9.6%]) or liver (P. vivax: +6.2% [CI -8.7% to +21.1%], P. falciparum: -1.4% [CI -4.6% to +1.8%]) following infection with either species. In participants with P. vivax, hemoglobin, hematocrit, and platelet count decreased from baseline at the time of postinoculation imaging. Decrements in hemoglobin and hematocrit were significantly greater in participants with P. vivax infection compared to P. falciparum. The main limitations of this study are the small sample size and the inability of this tracer to differentiate between host and parasite metabolic activity.

Conclusions: PET/MRI indicated greater splenic tropism and metabolic activity in early P. vivax infection compared to P. falciparum, supporting the hypothesis of splenic accumulation of P. vivax very early in infection. The absence of uptake in the bone marrow and liver suggests that, at least in early infection, these tissues do not harbor a large parasite biomass or do not provoke a prominent metabolic response. PET/MRI is a safe and noninvasive method to evaluate infection-associated organ changes in morphology and glucose metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / metabolism
  • Bone Marrow / parasitology*
  • Bone Marrow / pathology
  • Female
  • Glucose / metabolism*
  • Humans
  • Liver / metabolism
  • Liver / parasitology*
  • Liver / pathology
  • Magnetic Resonance Imaging
  • Malaria, Falciparum / parasitology*
  • Malaria, Falciparum / pathology
  • Malaria, Falciparum / physiopathology
  • Malaria, Vivax / parasitology*
  • Malaria, Vivax / pathology
  • Malaria, Vivax / physiopathology
  • Male
  • Plasmodium falciparum
  • Plasmodium vivax
  • Positron-Emission Tomography
  • Prospective Studies
  • Queensland
  • Spine / metabolism
  • Spine / parasitology
  • Spine / pathology
  • Spleen / metabolism
  • Spleen / parasitology*
  • Spleen / pathology
  • Young Adult

Substances

  • Glucose

Associated data

  • ClinicalTrials.gov/NCT02867059
  • ANZCTR/ACTRN12616000174482
  • ANZCTR/ACTRN12619001085167

Grants and funding

This project was supported by a HIRF Seed Funding Grant, Metro North Hospital and Health Service (J.W) and by the Australian National Health and Medical Research Council (J.S.M #1135955, #1037304, #1132975, and N.M.A #1135820, 1098334). The clinical trials contributing participants were funded by the Australian National Health and Medical Research Council (J.S.M #1132975), the Bill and Melinda Gates Foundation (J.S.M OPP1111147) and the Global Health Innovative Technology Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.